The Efficacy of miR-20a as a Diagnostic and Prognostic Biomarker for Colorectal Cancer: A Systematic Review and Meta-Analysis

Laura Moody, Svyatoslav Dvoretskiy, Ruopeng An, Suparna Mantha, Yuan-Xiang Pan

Research output: Contribution to journalReview article

Abstract

Background: MicroRNAs have altered expression levels in various diseases and may play an important role in the diagnosis and prognosis of colorectal cancer (CRC). Methods: We systemically reviewed and quantitatively synthesized the scientific evidence pertaining to microRNA-20a (miR-20a) as a CRC biomarker. A keyword and reference search in PubMed yielded 32 studies, in which miR-20a was measured in feces, serum, or tumor tissue. Data were extracted from a total of 5014 cancer cases and 2863 controls. Results: Twenty out of 21 relevant studies found that miR-20a was upregulated in CRC patients compared to controls. Meta-analysis revealed a pooled miR-20a fold change of 2.45 (95% CI: 2.24–2.66) in CRC patients versus controls. To estimate sensitivity and specificity of miR-20a as a diagnostic biomarker of CRC, a pooled area under the receiver operating characteristic curve (AUROC) was calculated (0.70, 95% CI: 0.63–0.78). The prognostic capacity of miR-20a was assessed using hazard ratios (HRs) for the overall survival (OS). The meta-analysis estimated the pooled HR for OS to be 2.02 (95% CI: 0.90–3.14) in CRC patients with high miR-20a expression. Conclusions: miR-20a may be a valid biomarker for CRC detection but may not be a strong predictor of poor prognosis in CRC.

Original languageEnglish (US)
Article number1111
JournalCancers
Volume11
Issue number8
DOIs
StatePublished - Aug 3 2019

Fingerprint

MicroRNAs
Meta-Analysis
Colorectal Neoplasms
Biomarkers
Survival
Tumor Biomarkers
PubMed
Feces
ROC Curve
Neoplasms
Sensitivity and Specificity
Serum

Keywords

  • Colorectal cancer
  • Diagnosis
  • microRNA
  • miR-20a
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The Efficacy of miR-20a as a Diagnostic and Prognostic Biomarker for Colorectal Cancer : A Systematic Review and Meta-Analysis. / Moody, Laura; Dvoretskiy, Svyatoslav; An, Ruopeng; Mantha, Suparna; Pan, Yuan-Xiang.

In: Cancers, Vol. 11, No. 8, 1111, 03.08.2019.

Research output: Contribution to journalReview article

Moody, Laura ; Dvoretskiy, Svyatoslav ; An, Ruopeng ; Mantha, Suparna ; Pan, Yuan-Xiang. / The Efficacy of miR-20a as a Diagnostic and Prognostic Biomarker for Colorectal Cancer : A Systematic Review and Meta-Analysis. In: Cancers. 2019 ; Vol. 11, No. 8.
@article{a4001035b8744efcba787445826dd964,
title = "The Efficacy of miR-20a as a Diagnostic and Prognostic Biomarker for Colorectal Cancer: A Systematic Review and Meta-Analysis",
abstract = "Background: MicroRNAs have altered expression levels in various diseases and may play an important role in the diagnosis and prognosis of colorectal cancer (CRC). Methods: We systemically reviewed and quantitatively synthesized the scientific evidence pertaining to microRNA-20a (miR-20a) as a CRC biomarker. A keyword and reference search in PubMed yielded 32 studies, in which miR-20a was measured in feces, serum, or tumor tissue. Data were extracted from a total of 5014 cancer cases and 2863 controls. Results: Twenty out of 21 relevant studies found that miR-20a was upregulated in CRC patients compared to controls. Meta-analysis revealed a pooled miR-20a fold change of 2.45 (95{\%} CI: 2.24–2.66) in CRC patients versus controls. To estimate sensitivity and specificity of miR-20a as a diagnostic biomarker of CRC, a pooled area under the receiver operating characteristic curve (AUROC) was calculated (0.70, 95{\%} CI: 0.63–0.78). The prognostic capacity of miR-20a was assessed using hazard ratios (HRs) for the overall survival (OS). The meta-analysis estimated the pooled HR for OS to be 2.02 (95{\%} CI: 0.90–3.14) in CRC patients with high miR-20a expression. Conclusions: miR-20a may be a valid biomarker for CRC detection but may not be a strong predictor of poor prognosis in CRC.",
keywords = "Colorectal cancer, Diagnosis, microRNA, miR-20a, Prognosis",
author = "Laura Moody and Svyatoslav Dvoretskiy and Ruopeng An and Suparna Mantha and Yuan-Xiang Pan",
year = "2019",
month = "8",
day = "3",
doi = "10.3390/cancers11081111",
language = "English (US)",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "8",

}

TY - JOUR

T1 - The Efficacy of miR-20a as a Diagnostic and Prognostic Biomarker for Colorectal Cancer

T2 - A Systematic Review and Meta-Analysis

AU - Moody, Laura

AU - Dvoretskiy, Svyatoslav

AU - An, Ruopeng

AU - Mantha, Suparna

AU - Pan, Yuan-Xiang

PY - 2019/8/3

Y1 - 2019/8/3

N2 - Background: MicroRNAs have altered expression levels in various diseases and may play an important role in the diagnosis and prognosis of colorectal cancer (CRC). Methods: We systemically reviewed and quantitatively synthesized the scientific evidence pertaining to microRNA-20a (miR-20a) as a CRC biomarker. A keyword and reference search in PubMed yielded 32 studies, in which miR-20a was measured in feces, serum, or tumor tissue. Data were extracted from a total of 5014 cancer cases and 2863 controls. Results: Twenty out of 21 relevant studies found that miR-20a was upregulated in CRC patients compared to controls. Meta-analysis revealed a pooled miR-20a fold change of 2.45 (95% CI: 2.24–2.66) in CRC patients versus controls. To estimate sensitivity and specificity of miR-20a as a diagnostic biomarker of CRC, a pooled area under the receiver operating characteristic curve (AUROC) was calculated (0.70, 95% CI: 0.63–0.78). The prognostic capacity of miR-20a was assessed using hazard ratios (HRs) for the overall survival (OS). The meta-analysis estimated the pooled HR for OS to be 2.02 (95% CI: 0.90–3.14) in CRC patients with high miR-20a expression. Conclusions: miR-20a may be a valid biomarker for CRC detection but may not be a strong predictor of poor prognosis in CRC.

AB - Background: MicroRNAs have altered expression levels in various diseases and may play an important role in the diagnosis and prognosis of colorectal cancer (CRC). Methods: We systemically reviewed and quantitatively synthesized the scientific evidence pertaining to microRNA-20a (miR-20a) as a CRC biomarker. A keyword and reference search in PubMed yielded 32 studies, in which miR-20a was measured in feces, serum, or tumor tissue. Data were extracted from a total of 5014 cancer cases and 2863 controls. Results: Twenty out of 21 relevant studies found that miR-20a was upregulated in CRC patients compared to controls. Meta-analysis revealed a pooled miR-20a fold change of 2.45 (95% CI: 2.24–2.66) in CRC patients versus controls. To estimate sensitivity and specificity of miR-20a as a diagnostic biomarker of CRC, a pooled area under the receiver operating characteristic curve (AUROC) was calculated (0.70, 95% CI: 0.63–0.78). The prognostic capacity of miR-20a was assessed using hazard ratios (HRs) for the overall survival (OS). The meta-analysis estimated the pooled HR for OS to be 2.02 (95% CI: 0.90–3.14) in CRC patients with high miR-20a expression. Conclusions: miR-20a may be a valid biomarker for CRC detection but may not be a strong predictor of poor prognosis in CRC.

KW - Colorectal cancer

KW - Diagnosis

KW - microRNA

KW - miR-20a

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85070773813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070773813&partnerID=8YFLogxK

U2 - 10.3390/cancers11081111

DO - 10.3390/cancers11081111

M3 - Review article

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 8

M1 - 1111

ER -